China Resources Double-Crane Pharmaceutical Co.,Ltd.

Shanghai Stock Exchange 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2023: 8.64%

China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) is 8.64% for the year ending December 31, 2023, a 6.02% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was 8.15%, a 19.09% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was 6.84%, a -15.49% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was 8.10%, a -13.48% change year over year.
  • China Resources Double-Crane Pharmaceutical Co.,Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was 9.36%, a -0.44% change year over year.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
Loading...
Shanghai Stock Exchange: 600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

CEO Mr. Wenchao Lu
IPO Date May 22, 1997
Location China
Headquarters No. 1, Lize East 2nd Road
Employees 12,269
Sector Health Care
Industries
Description

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

Similar companies

600058.SS

Minmetals Development Co., Ltd.

USD 0.95

1.76%

600085.SS

Beijing Tongrentang Co., Ltd

USD 5.16

2.25%

600007.SS

China World Trade Center Co., Ltd.

USD 3.20

0.78%

600056.SS

China Meheco Group Co., Ltd.

USD 1.47

2.19%

600008.SS

Beijing Capital Eco-environment Protection Group Co.,ltd.

USD 0.42

1.31%

StockViz Staff

January 16, 2025

Any question? Send us an email